Ligand-based virtual screening, parallel solution-phase and microwave-assisted synthesis as tools to identify and synthesize new inhibitors of Mycobacterium tuberculosis

ChemMedChem

Volumn 1, Issue 9, 2006, Pages 973-989

  Manetti, Fabrizio ^a   Magnani, Matteo ^a   Castagnolo, Daniele ^a   Passalacqua, Laura ^a   Botta, Maurizio ^a   Corelli, Federico ^a   Saddi, Manuela ^b   Deidda, Delia ^b   De Logu, Alessandro ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Drug design; Ligand based virtual screening; Medicinal chemistry; Molecular descriptors; Molecular diversity

Indexed keywords

LIGAND; TUBERCULOSTATIC AGENT;

ARTICLE; ARTIFICIAL INTELLIGENCE; BIOLOGY; COMPUTER SIMULATION; DRUG EFFECT; DRUG SCREENING; FACTUAL DATABASE; MICROBIOLOGICAL EXAMINATION; MICROWAVE RADIATION; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; SOLUTION AND SOLUBILITY; SYNTHESIS;

ANTITUBERCULAR AGENTS; ARTIFICIAL INTELLIGENCE; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; LIGANDS; MICROBIAL SENSITIVITY TESTS; MICROWAVES; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM TUBERCULOSIS; SOLUTIONS;

EID: 33749005650     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200600026     Document Type: Article

References (57)

1. D. Maher, M. Raviglione, Clin. Chest Med. 2005, 26, 167-182.
2. World Health Organization: Global Tuberculosis Control: Surveillance, Planning, Financing WHO Report, 2004, Geneva, Switzerland.
3. World Health Organization: The World Health Organization Global Tuberculosis Program, 2003. http://www.who.int/gtb/.
4. M. A. Espinal, Tuberculosis 2003, 83, 44-51.
5. a) T. R. Frieden, S. S. Munsiff, Clin. Chest Med. 2005, 26, 197-205;
6. b) W. J. Burman, Clin. Chest Med. 2005, 26, 283-294.
7. R. J. O'Brien, P. P. Nunn, Am. J. Respir. Crit. Care Med. 2001, 1635, 1055-1058.
8. F. Manetti, F. Corelli, M. Biava, R. Fioravanti, G. C. Porretta, M. Botta, Farmaco 2000, 55, 484-491.
9. M. Biava, R. Fioravanti, G. C. Porretta, D. Deidda, G. Lampis, R. Pompei, A. Tafi, F. Manetti, Med. Chem. Res. 2002, 12, 50-66.
10. M. Biava, G. C. Porretta, D. Deidda, R. Pompei, F. Manetti, A. Tafi, Bioorg. Med. Chem. 2003, 11, 515-520.
11. M. Biava, G. C. Porretta, D. Deidda, R. Pompei, A. Tafi, F. Manetti, Bioorg. Med. Chem. 2004, 12, 1453-1458.
12. M. Biava, G. C. Porretta, G. Poce, D. Deidda, R. Pompei, A. Tafi, F. Manetti, Bioorg. Med. Chem. 2005, 13, 1221-1230.
13. S. Meiering, O. Inhoff, J. Mies, A. Vincek, G. Garcia, B. Kramer, M. Dormeyer, R. L. Krauth-Siegel, J. Med. Chem. 2005, 48, 4793-4802.
14. J. H. van Drie, M. S. Lajiness, Drug Discovery Today 1998, 3, 274-283.
15. Recursive partitioning-centered virtual screening (RPCVS) protocol is a term used in the text and in Figures 1, 2, and 3 to outline a three-step virtual screening procedure consisting of: 1) the application of Lipinski's rule of five (due to the high lipophilicity of the mycobacterial cell wall, log P was raised from 5 to 6), 2) the classification of compounds according to the recursive partitioning (RP) model, and 3) the computation of the penalty factor.
16. R. J. O'Brien, M. Spigelman, Clin. Chest Med. 2005, 26, 327-340.
17. F. L. Stahura, J. Bajorath, Curr. Pharm. Des. 2005, 11, 1189-1202.
18. Further information is available at: http://www.asinex.com/prod/gold. html.
19. Separate lists containing: 1) references to papers in which compounds have been collected to build the learning set, 2) fragments used in the generation of LL, and 3) databases of commercially available compounds will be provided upon request.
20. A similar approach was recently reported (Ref. [37]), based on the classification of compounds as active, moderately active, and inactive.
21. Aimed at elaborating a ligand-based virtual screening procedure, the objective of the first part of our work was the collection of a huge set of compounds along with their MIC values suitable for the generation of a statistical model, without reference to their (known or unknown) mechanisms of action. Consistent with this collection criterion, we analyzed data by means of a recursive partitioning technique, which is able, in principle, not only to account for multiple structurally diverse classes of compounds and to tolerate a certain amount of erroneous input data, but also to deal with different mechanisms of action, as reported in: a) D. Horvath, SAR QSAR Environ. Res. 2001, 12, 181-212;
22. b) S. S. Young, C. E. Keefer, Computation and analysis of large chemistry data sets. Chemical Data Analysis in the Large: The Challenge of the Automation Age. International Workshop, May 22nd-26th, 2000, Bozen, Italy. http://www.beilstein-institut.de/bozen2000/proceedings/young/young.htm;
23. c) A. Rusinko III; M. W. Farmen, C. G. Lambert, P. L. Brown, S. S. Young, J. Chem. Int. Model. 1999, 39, 1017-1026.
24. Calculation of the overall prediction parameter provides information on the accuracy of the model in predicting properties of the whole set of compounds.
25. T. Langer, R. D. Hoffmann, Curr. Pharm. Des. 2001, 7, 509-527.
26. R. D. Brown, M. Hassan, M. Waldman, J. Mol. Graphics Modell. 2000, 18, 427-437.
27. E. A. Jamois, C. T. Lin, M. Waldman, J. Mol. Graphics Modell. 2003, 22, 141-149.
28. J. M. Barnard, G. M. Downs, A. von Scholley-Pfab, R. D. Brown, J. Mol. Graphics Modell. 2000, 18, 452-463.
29. J. M. Barnard, G. M. Downs, J. Chem. Inf. Comput. Sci. 1997, 37, 141-142.
30. S. A. Wildman, G. M. Crippen, J. Chem. Inf. Comput. Sci. 1999, 39, 868-873.
31. M. Hassan, J. P. Bielawski, J. C. Hempel, M. Waldman, Mol. Diversity 1996, 2, 64-74.
32. A. K. Ghose, V. N. Viswanadhan, J. J. Wendoloski, J. Phys. Chem. A 1998, 102, 3762-3772.
33. Penalty factor values in the SL range from 0.373 to 5.530. The threshold value of the penalty factors was arbitrarily defined, so as to result in a reasonably restricted number of selected compounds. 668 compounds of the SL had a penalty factor value less than 1 (about 13%).
34. Details of the software can be found at the Molecular Discovery web page: http://www.moldiscovery.com/softvolsurf.php.
35. M. A. Johnson, G. M. Maggiora, Concepts and applications of molecular similarity, Wiley, New York, 1990.
36. a) R. Ragno, G. R. Marshall, R. Di Santo, R. Costi, S. Massa, R. Pompei, M. Artico, Bioorg. Med. Chem. 2000, 8, 1423-1432, and references cited therein;
37. b) G. Sbardella, A. Mai, M. Artico, R. Loddo, M. G. Setzu, P. La Colla, Bioorg. Med. Chem. Lett. 2004, 14, 1537-1541;
38. c) A. Nayyar, R. Jain, Curr. Med. Chem. 2005, 12, 1873-1886.
39. As an example, BM212 was one of the first pyrrole derivatives, described in: D. Deidda, G. Lampis, R. Fioravanti, M. Biava, G. C. Porretta, S. Zanetti, R. Pompei, Antimicrob. Agents Chemother. 1998, 42, 3035-3037.
40. A novel pyrrole compound, LL4858, is currently in development by Lupin Limited (US 2005 026128A1, WO 2004 026828).
41. a) G. Menozzi, L. Merello, P. Fossa, S. Schenone, A. Ranise, L. Mosti, F. Bondavalli, R. Loddo, C. Murgioni, V. Mascia, P. La Colla, E. Tamburini, Bioorg. Med. Chem. 2004, 12, 5465-5483;
42. b) M. G. Mamolo, D. Zampieri, V. Falagiani, L. Vio, E. Banfi, Farmaco 2001, 56, 593-599.
43. I. Ghosh, O. Prakash, J. Chem. Inf. Model. 2006, 46, 17-23.
44. G. C. Porretta, M. Biava, R. Fioravanti, A. Villa, N. Simonetti, Farmaco 1991, 46, 987-995.
45. R. Fioravanti, M. Biava, G. C. Porretta, G. Lampis, C. Maullu, R. Pompei, Med. Chem. Res. 1999, 9, 249-266.
46. R. Ballini, M. Petrini, E. Marcantoni, G. Rosini, Synthesis 1988, 3, 231-233.
47. a) M. Radi, E. Petricci, G. Maga, F. Corelli, M. Botta, J. Comb. Chem. 2005, 7, 117-122;
48. b) E. Petricci, C. Mugnaini, M. Radi, F. Corelli, M. Botta, J. Org. Chem. 2004, 69, 7880-7887;
49. c) D. Castagnolo, M. L. Renzulli, E. Galletti, F. Corelli, M. Botta, Tetrahedron: Asymmetry 2005, 16, 2893-2896.
50. D. Villemin, B. Labiad, Synth. Commun. 1990, 20, 3213-3218.
51. W. Holzer, R. M. Claramunt, M. Pérez-Torralba, D. Guggi, T. Brehmer, J. Org. Chem. 2003, 68, 7943-7950.
52. J. J. Irwin, B. K. Shoichet, J. Chem. Inf. Model. 2005, 45, 177-182.
53. 2 and Catalyst are distributed by Accelrys, Inc., San Diego, CA.
54. G. Cruciani, P. Crivori, P.-A. Carrupt, B. Testa, J. Mol. Struct. 2000, 503, 17-30.
55. Compounds 8a and 8b proved inseparable by flash chromatography; they were used in the next step as a mixture.
56. C. Jagannath, V. M. Reddy, P. R. Gangadharam, J. Antimicrob. Chemother. 1995, 35, 381-390.
57. A. De Logu, V. Onnis, B. Saddi, C. Congiu, M. L. Schivo, M. T. Cocco, J. Antimicrob. Chemother. 2002, 49, 275-282.